Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Classical hematology 1

Conditions

Glioblastoma 3Breast Neoplasms 3Brain Neoplasms 3Recurrence 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Gliosarcoma 2Breast Neoplasms, Male 2Squamous Cell Carcinoma of Head and Neck 1Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Inflammatory Breast Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Congenital Abnormalities 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Azacitidine 26venetoclax 12Peripheral Blood Stem Cell Transplantation 12fludarabine phosphate 10Mycophenolic Acid 9Whole-Body Irradiation 8Cyclosporine 8Cytarabine 7Cyclophosphamide 6Filgrastim 5Decitabine 5Busulfan 5Methotrexate 4fludarabine 3aldesleukin 3Tacrolimus 3Granulocyte Colony-Stimulating Factor 3Flow Cytometry 3Cytogenetic Analysis 3Cyclosporins 3Biopsy 3tipifarnib 2tagraxofusp 2ruxolitinib 2quizartinib 2eprenetapopt 2axatilimab 2X-Rays 2Transplantation 2Topotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myelomonocytic, Chronic × tipifarnib × Clear all
NCT02210858 2018-06-04

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1/2 Completed
31 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00096122 2014-05-26

Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
95 enrolled 5 charts
Classical hematologyOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡